相似文献
1
Potential Biomarkers for NSAID-Exacerbated Respiratory Disease.
Mediators Inflamm. 2017;2017:8160148. doi: 10.1155/2017/8160148. Epub 2017 Aug 9.
2
Nonsteroidal anti-inflammatory drug (NSAID) exacerbated respiratory disease phenotype: Topical NSAID and asthma control - A possible oversight link.
Respir Med. 2016 Sep;118:1-3. doi: 10.1016/j.rmed.2016.07.004. Epub 2016 Jul 9.
3
From "Samter's Triad" to "NERD": The Long and Winding Road to Understanding Aspirin-Exacerbated Respiratory Disease.
Immunol Allergy Clin North Am. 2016 Nov;36(4):xiii-xiv. doi: 10.1016/j.iac.2016.08.002.
4
Nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease in adolescents.
Int Forum Allergy Rhinol. 2015 May;5(5):392-8. doi: 10.1002/alr.21494. Epub 2015 Mar 6.
5
Prostaglandin E decrease in induced sputum of hypersensitive asthmatics during oral challenge with aspirin.
Allergy. 2019 May;74(5):922-932. doi: 10.1111/all.13671. Epub 2018 Dec 5.
6
[The value of aspirin challenge tests in the diagnosis of non-steroidal anti-inflammatory drugs-exacerbated respiratory disease].
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023 Aug 7;58(8):741-746. doi: 10.3760/cma.j.cn115330-20230120-00035.
7
Nonsteroidal anti-inflammatory drug-exacerbated respiratory disease: diagnosis and current management.
Pol Arch Intern Med. 2023 Sep 29;133(9). doi: 10.20452/pamw.16544. Epub 2023 Aug 7.
8
Identification of phenotypic clusters of nonsteroidal anti-inflammatory drugs exacerbated respiratory disease.
Allergy. 2017 Apr;72(4):616-626. doi: 10.1111/all.13075. Epub 2016 Dec 1.
9
Diagnostic Evaluation in Aspirin-Exacerbated Respiratory Disease.
Immunol Allergy Clin North Am. 2016 Nov;36(4):657-668. doi: 10.1016/j.iac.2016.06.003. Epub 2016 Sep 13.
10
Heterogeneity of NSAID-Exacerbated Respiratory Disease: has the time come for subphenotyping?
Curr Opin Pulm Med. 2019 Jan;25(1):64-70. doi: 10.1097/MCP.0000000000000530.
引用本文的文献
1
[Expert consensus on the diagnosis and treatment of respiratory diseases exacerbated by nonsteroidal anti-inflammatory drugs （2024, Chengdu）].
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2024 Jun;38(6):453-462. doi: 10.13201/j.issn.2096-7993.2024.06.001.
2
New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis.
Clin Sci (Lond). 2023 May 18;137(9):727-753. doi: 10.1042/CS20190281.
3
Bacterial Extracellular Vesicles: A Candidate Molecule for the Diagnosis and Treatment of Allergic Diseases.
Allergy Asthma Immunol Res. 2023 May;15(3):279-289. doi: 10.4168/aair.2023.15.3.279.
4
Immunologic Basis of Type 2 Biologics for Severe Asthma.
Immune Netw. 2022 Dec 5;22(6):e45. doi: 10.4110/in.2022.22.e45. eCollection 2022 Dec.
5
Immune Metabolism in TH2 Responses: New Opportunities to Improve Allergy Treatment - Disease-Specific Findings (Part 1).
Curr Allergy Asthma Rep. 2023 Jan;23(1):29-40. doi: 10.1007/s11882-022-01057-8. Epub 2022 Nov 28.
6
Emerging Biomarkers Beyond Leukotrienes for the Management of Nonsteroidal Anti-inflammatory Drug (NSAID)-Exacerbated Respiratory Disease.
Allergy Asthma Immunol Res. 2022 Mar;14(2):153-167. doi: 10.4168/aair.2022.14.2.153.
7
Potential Metabolic Biomarkers in Adult Asthmatics.
Metabolites. 2021 Jun 30;11(7):430. doi: 10.3390/metabo11070430.
8
Biomarkers for Severe Asthma: Lessons From Longitudinal Cohort Studies.
Allergy Asthma Immunol Res. 2021 May;13(3):375-389. doi: 10.4168/aair.2021.13.3.375.
本文引用的文献
1
Exploration of the Sphingolipid Metabolite, Sphingosine-1-phosphate and Sphingosine, as Novel Biomarkers for Aspirin-exacerbated Respiratory Disease.
Sci Rep. 2016 Nov 10;6:36599. doi: 10.1038/srep36599.
2
Identification of phenotypic clusters of nonsteroidal anti-inflammatory drugs exacerbated respiratory disease.
Allergy. 2017 Apr;72(4):616-626. doi: 10.1111/all.13075. Epub 2016 Dec 1.
3
Lipid Mediators in Aspirin-Exacerbated Respiratory Disease.
Immunol Allergy Clin North Am. 2016 Nov;36(4):749-763. doi: 10.1016/j.iac.2016.06.009.
4
Aspirin-Exacerbated Respiratory Disease as an Endotype of Chronic Rhinosinusitis.
Immunol Allergy Clin North Am. 2016 Nov;36(4):669-680. doi: 10.1016/j.iac.2016.06.004. Epub 2016 Sep 13.
5
Aspirin-exacerbated respiratory disease: an update.
Curr Opin Pulm Med. 2017 Jan;23(1):89-96. doi: 10.1097/MCP.0000000000000328.
6
Using Periostin as a Biomarker in the Treatment of Asthma.
Allergy Asthma Immunol Res. 2016 Nov;8(6):491-8. doi: 10.4168/aair.2016.8.6.491.
7
Eicosanoid Mediators in the Airway Inflammation of Asthmatic Patients: What is New?
Allergy Asthma Immunol Res. 2016 Nov;8(6):481-90. doi: 10.4168/aair.2016.8.6.481.
8
Metabolomic analysis identifies potential diagnostic biomarkers for aspirin-exacerbated respiratory disease.
Clin Exp Allergy. 2017 Jan;47(1):37-47. doi: 10.1111/cea.12797. Epub 2016 Sep 27.
9
Aspirin or Nonsteroidal Anti-inflammatory Drug-Exacerbated Chronic Rhinosinusitis.
J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):590-8. doi: 10.1016/j.jaip.2016.04.011.
10
Update on the Management of Aspirin-Exacerbated Respiratory Disease.
Allergy Asthma Immunol Res. 2016 Jul;8(4):298-304. doi: 10.4168/aair.2016.8.4.298.
Zotero 插件